These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 17361995

  • 1. Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.
    Greco MN, Hawkins MJ, Powell ET, Almond HR, de Garavilla L, Hall J, Minor LK, Wang Y, Corcoran TW, Di Cera E, Cantwell AM, Savvides SN, Damiano BP, Maryanoff BE.
    J Med Chem; 2007 Apr 19; 50(8):1727-30. PubMed ID: 17361995
    [Abstract] [Full Text] [Related]

  • 2. A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo.
    de Garavilla L, Greco MN, Sukumar N, Chen ZW, Pineda AO, Mathews FS, Di Cera E, Giardino EC, Wells GI, Haertlein BJ, Kauffman JA, Corcoran TW, Derian CK, Eckardt AJ, Damiano BP, Andrade-Gordon P, Maryanoff BE.
    J Biol Chem; 2005 May 06; 280(18):18001-7. PubMed ID: 15741158
    [Abstract] [Full Text] [Related]

  • 3. 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase.
    Combrink KD, Gülgeze HB, Meanwell NA, Pearce BC, Zulan P, Bisacchi GS, Roberts DG, Stanley P, Seiler SM.
    J Med Chem; 1998 Nov 19; 41(24):4854-60. PubMed ID: 9822554
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and evaluation of 4-amino-3,4-dihydro-2H-naphthalen-1-one derivatives as mast cell stabilising and anti-inflammatory compounds.
    Barlow JW, Walsh JJ.
    Eur J Med Chem; 2008 Dec 19; 43(12):2891-900. PubMed ID: 18406013
    [Abstract] [Full Text] [Related]

  • 5. The discovery of orally active triaminotriazine aniline amides as inhibitors of p38 MAP kinase.
    Leftheris K, Ahmed G, Chan R, Dyckman AJ, Hussain Z, Ho K, Hynes J, Letourneau J, Li W, Lin S, Metzger A, Moriarty KJ, Riviello C, Shimshock Y, Wen J, Wityak J, Wrobleski ST, Wu H, Wu J, Desai M, Gillooly KM, Lin TH, Loo D, McIntyre KW, Pitt S, Shen DR, Shuster DJ, Zhang R, Diller D, Doweyko A, Sack J, Baldwin J, Barrish J, Dodd J, Henderson I, Kanner S, Schieven GL, Webb M.
    J Med Chem; 2004 Dec 02; 47(25):6283-91. PubMed ID: 15566298
    [Abstract] [Full Text] [Related]

  • 6. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.
    Crane SN, Black WC, Palmer JT, Davis DE, Setti E, Robichaud J, Paquet J, Oballa RM, Bayly CI, McKay DJ, Somoza JR, Chauret N, Seto C, Scheigetz J, Wesolowski G, Massé F, Desmarais S, Ouellet M.
    J Med Chem; 2006 Feb 09; 49(3):1066-79. PubMed ID: 16451072
    [Abstract] [Full Text] [Related]

  • 7. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
    Grembecka J, Mucha A, Cierpicki T, Kafarski P.
    J Med Chem; 2003 Jun 19; 46(13):2641-55. PubMed ID: 12801228
    [Abstract] [Full Text] [Related]

  • 8. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
    Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH, Wright LL, Zhou HQ.
    J Med Chem; 2004 Jan 29; 47(3):588-99. PubMed ID: 14736240
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and SAR of arylaminoethyl amides as noncovalent inhibitors of cathepsin S: P3 cyclic ethers.
    Tully DC, Liu H, Chatterjee AK, Alper PB, Epple R, Williams JA, Roberts MJ, Woodmansee DH, Masick BT, Tumanut C, Li J, Spraggon G, Hornsby M, Chang J, Tuntland T, Hollenbeck T, Gordon P, Harris JL, Karanewsky DS.
    Bioorg Med Chem Lett; 2006 Oct 01; 16(19):5112-7. PubMed ID: 16876402
    [Abstract] [Full Text] [Related]

  • 10. Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells.
    He S, Gaça MD, McEuen AR, Walls AF.
    J Pharmacol Exp Ther; 1999 Nov 01; 291(2):517-23. PubMed ID: 10525066
    [Abstract] [Full Text] [Related]

  • 11. Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor.
    Han Y, Belley M, Bayly CI, Colucci J, Dufresne C, Giroux A, Lau CK, Leblanc Y, McKay D, Therien M, Wilson MC, Skorey K, Chan CC, Scapin G, Kennedy BP.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3200-5. PubMed ID: 18477508
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
    Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni SS, Xu X, Chang W, Weerasena V, Turner R, Koelsch G, Bilcer G, Tang J.
    J Med Chem; 2007 May 17; 50(10):2399-407. PubMed ID: 17432843
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J, Dyckman AJ, Lin S, Wrobleski ST, Wu H, Gillooly KM, Kanner SB, Lonial H, Loo D, McIntyre KW, Pitt S, Shen DR, Shuster DJ, Yang X, Zhang R, Behnia K, Zhang H, Marathe PH, Doweyko AM, Tokarski JS, Sack JS, Pokross M, Kiefer SE, Newitt JA, Barrish JC, Dodd J, Schieven GL, Leftheris K.
    J Med Chem; 2008 Jan 10; 51(1):4-16. PubMed ID: 18072718
    [Abstract] [Full Text] [Related]

  • 14. Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.
    Terasaka T, Okumura H, Tsuji K, Kato T, Nakanishi I, Kinoshita T, Kato Y, Kuno M, Seki N, Naoe Y, Inoue T, Tanaka K, Nakamura K.
    J Med Chem; 2004 May 20; 47(11):2728-31. PubMed ID: 15139750
    [Abstract] [Full Text] [Related]

  • 15. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG.
    J Med Chem; 2008 Mar 27; 51(6):1637-48. PubMed ID: 18278858
    [Abstract] [Full Text] [Related]

  • 16. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X.
    J Med Chem; 2008 Mar 27; 51(6):1681-94. PubMed ID: 18321037
    [Abstract] [Full Text] [Related]

  • 17. Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.
    Barrett DG, Catalano JG, Deaton DN, Long ST, Miller LR, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ.
    Bioorg Med Chem Lett; 2004 May 17; 14(10):2543-6. PubMed ID: 15109647
    [Abstract] [Full Text] [Related]

  • 18. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors.
    Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G.
    J Med Chem; 2006 Jul 27; 49(15):4455-8. PubMed ID: 16854050
    [Abstract] [Full Text] [Related]

  • 19. Potency variation of small-molecule chymase inhibitors across species.
    Kervinen J, Crysler C, Bayoumy S, Abad MC, Spurlino J, Deckman I, Greco MN, Maryanoff BE, de Garavilla L.
    Biochem Pharmacol; 2010 Oct 01; 80(7):1033-41. PubMed ID: 20599788
    [Abstract] [Full Text] [Related]

  • 20. The human mast cell chymase gene (CMA1): mapping to the cathepsin G/granzyme gene cluster and lineage-restricted expression.
    Caughey GH, Schaumberg TH, Zerweck EH, Butterfield JH, Hanson RD, Silverman GA, Ley TJ.
    Genomics; 1993 Mar 01; 15(3):614-20. PubMed ID: 8468056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.